Want to see JP:4516 full AI Analyst Report?
4516 Stock Chart & Stats
¥5650.00
-¥42.00(-1.04%)
At close: 4:00 PM EST
¥5650.00
-¥42.00(-1.04%)
Day’s Range― - ―
52-Week Range¥3,075.00 - ¥6,529.00
Previous CloseN/A
Volume198.40K
Average Volume (3M)252.03K
Market Cap
¥229.00B
Enterprise Value¥200.69K
Total Cash (Recent Filing)¥76.59B
Total Debt (Recent Filing)¥2.57B
Price to Earnings (P/E)7.7
Beta0.34
Next Earnings
Nov 18, 2026EPS Estimate
117.41Next Dividend Ex-DateN/A
Dividend Yield3.65%
Share Statistics
EPS (TTM)441.04
Shares Outstanding70,251,490
10 Day Avg. Volume218,840
30 Day Avg. Volume252,026
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)1.18
Price to Sales (P/S)2.02
P/FCF Ratio14.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,300.00Price Target Upside-23.89% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)435.96
Revenue Forecast (FY)¥191.57B
Bulls Say, Bears Say
Bulls Say
High MarginsSustained high gross (~66%) and operating (~19%) margins reflect pricing power in specialty pharmaceuticals and a favorable product mix. These margins provide durable capacity to fund R&D, support lifecycle management, and absorb reimbursement pressure, underpinning long-term profitability.
Very Low LeverageA fortress-like balance sheet with debt-to-equity near 0.9% gives substantial financial flexibility. Low leverage reduces default risk, supports investment or M&A optionality, and preserves capacity to maintain dividends or fund development even through sector or revenue cyclicality.
Strong Cash ConversionHigh free-cash-flow conversion (~89% of net income) signals earnings quality and resilient cash generation from operations. This durable cash conversion supports sustained R&D funding, capex, and shareholder distributions, and cushions the business against cyclical margin swings.
Bears Say
2026 Profit & FCF Step-downA material step-down in margins and FCF in 2026 indicates emerging structural pressures—costs, mix shifts, or higher investments—that could persist. If sustained, this reduces reinvestment capacity, limits excess cash for dividends or deals, and weakens the cushion from the previously strong financial profile.
Modest Top-line GrowthSlow revenue acceleration (just +2.8% in 2026 after a flat 2025) suggests growth is modest and may rely on limited products or incremental indications. Over months this raises execution risk: absent new approvals or geographic expansion, durable revenue growth could remain constrained and pressure long-term returns.
Declining ROEA falling ROE (≈10% from ≈13%) signals deteriorating efficiency of equity capital, whether from margin compression or a larger equity base. Persistently lower ROE can limit shareholder value creation and indicates management must either improve margins, accelerate growth, or optimize capital allocation to restore returns.
Nippon Shinyaku Co., Ltd. News
4516 FAQ
What was Nippon Shinyaku Co., Ltd.’s price range in the past 12 months?
Nippon Shinyaku Co., Ltd. lowest stock price was ¥3075.00 and its highest was ¥6529.00 in the past 12 months.
What is Nippon Shinyaku Co., Ltd.’s market cap?
Nippon Shinyaku Co., Ltd.’s market cap is ¥229.00B.
When is Nippon Shinyaku Co., Ltd.’s upcoming earnings report date?
Nippon Shinyaku Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 101 days.
How were Nippon Shinyaku Co., Ltd.’s earnings last quarter?
Nippon Shinyaku Co., Ltd. released its earnings results on Aug 06, 2026. The company reported ¥149.98 earnings per share for the quarter, beating the consensus estimate of ¥98.856 by ¥51.124.
Is Nippon Shinyaku Co., Ltd. overvalued?
According to Wall Street analysts Nippon Shinyaku Co., Ltd.’s price is currently Overvalued.
Does Nippon Shinyaku Co., Ltd. pay dividends?
Nippon Shinyaku Co., Ltd. pays a Semiannually dividend of ¥62 which represents an annual dividend yield of 3.65%. See more information on Nippon Shinyaku Co., Ltd. dividends here
What is Nippon Shinyaku Co., Ltd.’s EPS estimate?
Nippon Shinyaku Co., Ltd.’s EPS estimate is 117.41.
How many shares outstanding does Nippon Shinyaku Co., Ltd. have?
Nippon Shinyaku Co., Ltd. has 70,251,490 shares outstanding.
What happened to Nippon Shinyaku Co., Ltd.’s price movement after its last earnings report?
Nippon Shinyaku Co., Ltd. reported an EPS of ¥149.98 in its last earnings report, beating expectations of ¥98.856. Following the earnings report the stock price went up 1.9%.
Which hedge fund is a major shareholder of Nippon Shinyaku Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4516
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.
4516 Stock 12 Month Forecast
Average Price Target
¥4,300.00
▼(-23.89% Downside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Toho Holdings Co., Ltd.
―






